### Highlights of the NARMS Retail 2010 Report

# Salmonella<sup>1</sup>

Salmonella serotypes Typhimurium, Saintpaul, and Heidelberg accounted for 44.5% of retail meat isolates (Table 6). The prevalence of serotype IIIa 18:z4,z23:- increased from 0.9% in 2003 to 6.3% in 2010, outnumbering Kentucky and removing it from the top 5 serotypes. Saintpaul remains the most common serotype in ground turkey, which was first seen in 2009. Heidelberg prevalence among all retail meat continues to decrease from 22.8 to 9% from 2002 through 2010.

First-line antimicrobial agents recommended for treating salmonellosis are ciprofloxacin, ceftriaxone and trimethoprim-sulfamethoxazole.<sup>2</sup>

- Quinolones Resistance to nalidixic acid corresponds to decreased fluoroquinolone susceptibility; however, fluoroquinolone resistance has never been detected in Salmonella recovered from any retail meat since the program began in 2002. Only 0.3% (1/400) of Salmonella from all sources was nalidixic acid resistant (Table 7).
- Ocephalosporins Third-generation cephalosporin resistance rose in chicken breast (10-34.5%) and ground turkey (8.1-16.3%) isolates from 2002 to 2010 (p < 0.05).
- There were significant increases in ampicillin resistance among chicken breast (16.7–39.2%, p < 0.05) and ground turkey isolates (16.2–48%, p<0.001) from 2002 to 2010.
- Multidrug Resistance 43.3% of chicken breast isolates were resistant to ≥ 3 antimicrobial classes in 2010 compared to 33.7% in ground turkey. More than 29% of chicken breast isolates showed resistance to ≥ 5 classes in 2010 (Table 10), to which serotype Typhimurium accounts for more than half of isolates resistant to ≥ 4 classes (Table 8). Serotype Albert was isolated from ground turkey for the first time since 2002 and was resistant to all 8 classes of antimicrobials tested.
- Salmonella isolates susceptible to all antimicrobials decreased in pork chops (50–35%) from 2009 to 2010 (Table 10). Meanwhile, Salmonella pansusceptibility increased among chicken breast (29–35.7%) and ground turkey (22.3–30.7%) isolates.

## Campylobacter<sup>3</sup>

More than 90% of *Campylobacter* are recovered from chicken breast each year and of those isolates, the proportion of *C. jejuni* to *C. coli* is about 2:1 (Table 12).

Macrolides and fluoroquinolones are used in the treatment of *Campylobacter* infections. It is well known that *C. coli* tend to be more resistant than *C. jejuni* regardless of source, and this is reflected in the 2010 NARMS retail data with the exception of quinolones and tetracycline.

- Macrolide resistance in chicken breast isolates was seen in 4.1% of *C. coli* and 0.6% of *C. jejuni* in 2010, with no significant changes over time (Table 15).
- Ciprofloxacin resistance in *C. coli* from chicken breast rose from 10% in 2002 to its highest peak of 29.1% in 2005. Since the fluoroquinolone ban in September 2005, ciprofloxacin resistance in *C. coli* has decreased to 13.5% in 2010 (Table 15), while

<sup>&</sup>lt;sup>1</sup> Nearly all salmonellae were recovered from poultry. Due to the low recovery from ground beef and pork chops (< 2%), statistical analysis of trends in resistance from these sources should be considered with caution.

<sup>&</sup>lt;sup>2</sup> IDSA, Practice Guidelines for the Management of Infectious Diarrhea. *Clinical Infectious Diseases* 2001; 32:331–50.

<sup>&</sup>lt;sup>3</sup> Ground beef and pork chop samples are no longer cultured for *Campylobacter*, due to their low recovery (<0.5%) from 2002–2007.

- resistance in *C. jejuni* significantly increased from 15.2–22.5% from 2002 to 2010 (p=0.0003).
- Tetracycline resistance decreased in *C. jejuni* (45.8–36.3%) compared to 2009 and *C. coli* remained level at 39.2%.
- o Gentamicin resistance in *C. coli* has increased to 12.8% in 2010, up from 0.7% in 2007 when it first appeared in NARMS retail meat (p < 0.0001).
- Multidrug resistance is rare in *Campylobacter*. There were only 9 (of 555) *Campylobacter* isolates from poultry resistant to ≥ 3 antimicrobial classes in 2010 (Table 16).

#### Enterococcus

*E. faecalis* (72.8% [1221/1677]) was more prevalent than *E. faecium* (27% [335/1677]) in 2010 (Table 18). Chicken breast was the only meat type where *E. faecium* was more prevalent than *E. faecalis*.

*Enterococcus* is used as a sentinel for antibiotic selection pressures by compounds with gram-positive activity. This spectrum of activity is exhibited by many antimicrobials used in food animal production; and the same classes of antibiotics are also used to treat human infections.

- No isolates were resistant to vancomycin or linezolid (Table 19). These classes of compounds are critically important in human medicine but are not used in food animal production.
- Since 2002, streptogramin resistance has significantly decreased (p < 0.05) in chicken breast (56.3–27.1%), ground beef (46.2–2.3%), and pork chop (27.2–3.8%) but has remained above 50% in turkey isolates.
- E. faecalis from poultry showed markedly higher aminoglycoside and macrolide resistance than E. faecium, with exception of streptomycin. E. faecium had much higher resistance to nitrofurantoin, penicillin and ciprofloxacin from all sources compared to E. faecalis (Table 20.1-2).
- Multidrug resistance from 2002–2010 was highest in *E. faecium* isolates from poultry in comparison to multidrug resistant *E. faecalis* (Table 21.1-2).

#### Escherichia coli

*E. coli* are common in all retail meat products tested in NARMS. Of 1,840 retail meats tested in 2010 64% were culture positive for *E. coli*, with pork chops having the lowest prevalence (39.8%) and ground turkey with the highest (80.2%).

- o Ceftriaxone resistance among *E. coli* isolates from chicken breast is consistently higher than any other retail meat tested (Table 24).
- Ciprofloxacin resistance remained low (< 1.0%) among E. coli isolates (Table 24).</li>
- o From 2002–2005, nalidixic acid resistance in *E. coli* from chicken breast increased from 2.8–6.6% and increased in ground turkey from 4.3–10.4%. Since the fluoroquinolone ban in September 2005, resistance has decreased to 3.6% in chicken breast and 2.7% in ground turkey (Table 24). Nalidixic acid resistance in ground beef and pork chops remains < 2%.
- Gentamicin resistance is much higher in retail poultry isolates (> 20%) than ground beef and pork chop isolates (< 5%, Table 24).</li>
- o A highly statistically significant trend (p < 0.0001) in ampicillin resistance was seen among ground turkey with 52.6% resistance in 2010, up from 31.3% in 2002.